Amplia Therapeutics Ltd (ASX: ATX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Amplia Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Amplia Therapeutics Ltd (ASX: ATX)
Latest News

Share Market News
Why the Amplia (ASX:ATX) share price is rocketing 41% higher today

Share Market News
Here's why the Amplia (ASX:ATX) share price is up 9% today
Share Market News
Amplia Therapeutics share price up 16% in 2 days as former Macquarie CEO takes substantial stake
Share Market News
US congressman resigns over ASX insider trading penny stock scandal
Share Market News
ASX Watergate Arrest: The alleged insider trading at Innate Immunotherapeutics Ltd (ASX:IIL)
⏸️ Investing
Cann Group Ltd is one of 64 new shares added to the All Ordinaries this quarter
⏸️ Investing
Were these the 3 worst shares on the ASX in 2017?
⏸️ Investing
These are the 5 biggest losers on the All Ordinaries in the last 12 months
⏸️ Investing
One crucial thing to consider before investing in risky biotech shares
⏸️ Investing
The 3 biggest investing mistakes you can make
⏸️ Investing
Here's how to get rich quick (and stay poor forever)
⏸️ Investing
Warning: Every investor should read this before buying speculative biotech companies
ATX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Amplia Therapeutics Ltd
Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.
ATX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Nov 2023 | $0.08 | $0.00 | 0.00% | 6,639 | $0.08 | $0.08 | $0.07 |
27 Nov 2023 | $0.08 | $-0.01 | -12.50% | 146,068 | $0.07 | $0.08 | $0.07 |
24 Nov 2023 | $0.08 | $0.00 | 0.00% | 5,107 | $0.08 | $0.08 | $0.08 |
23 Nov 2023 | $0.08 | $0.00 | 0.00% | 10,000 | $0.08 | $0.08 | $0.08 |
22 Nov 2023 | $0.08 | $0.01 | 13.33% | 29,635 | $0.08 | $0.08 | $0.07 |
20 Nov 2023 | $0.08 | $0.00 | 0.00% | 215,389 | $0.08 | $0.08 | $0.08 |
17 Nov 2023 | $0.07 | $0.00 | 0.00% | 23,842 | $0.07 | $0.07 | $0.07 |
15 Nov 2023 | $0.07 | $-0.01 | -13.16% | 287,039 | $0.08 | $0.08 | $0.06 |
13 Nov 2023 | $0.08 | $0.00 | 0.00% | 86,800 | $0.08 | $0.08 | $0.08 |
10 Nov 2023 | $0.08 | $0.00 | 0.00% | 28,476 | $0.08 | $0.08 | $0.08 |
09 Nov 2023 | $0.08 | $0.00 | 0.00% | 121,461 | $0.08 | $0.08 | $0.08 |
08 Nov 2023 | $0.08 | $0.00 | 0.00% | 3,067 | $0.08 | $0.08 | $0.08 |
06 Nov 2023 | $0.08 | $0.00 | 0.00% | 10,120 | $0.08 | $0.08 | $0.08 |
03 Nov 2023 | $0.08 | $0.00 | 0.00% | 53,487 | $0.09 | $0.09 | $0.08 |
02 Nov 2023 | $0.08 | $0.00 | 0.00% | 15,870 | $0.08 | $0.08 | $0.08 |
31 Oct 2023 | $0.09 | $0.00 | 0.00% | 95,898 | $0.09 | $0.09 | $0.08 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
31 Aug 2023 | Robert Peach | Expiry | 480,000 | $42,240 |
Options expired.
|
29 Aug 2023 | Christopher Burns | Issued | 2,500,000 | $220,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Andrew John Cooke | Company Secretary | Oct 2013 |
Mr Cooke has experience in law, corporate finance, governance and compliance. As a Non-Executive Director and Company Secretary of a number of ASX listed companies he has over 25 years of boardroom experience and has developed a practical blend of legal and commercial acumen. He has served as a consultant to listed, public and private companies in the resources, property and biotech sectors focussing on stock exchange and regulatory compliance and a wide range of corporate transactions. Andrew has been the Company Secretary since 11 October 2013.
|
Dr John Lambert | Chief Executive Officer | Jun 2019 |
Dr Lambert was appointed CEO on 24 June 2019 and Managing Director on 6 February 2020. John has more than 18 years of drug discovery and development experience. His prior appointments included leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), primarily working on the development of respiratory antiviral drugs. As a Senior Director at Medicines Development for Global Health, he was a member of the team that received approval in 2018 from the US FDA for moxidectin as a treatment for river blindness. Prior to working in industry he was an academic researcher in organic, medicinal and biological chemistry (University of Melbourne, ANU and Harvard University). He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
|
Dr Robert Peach | Non-Executive Director | Sep 2015 |
Dr Peach has over 25 years of drug discovery and development experience in the pharmaceutical and biotechnology industry. He was appointed as an Independent Non-Executive Director on 2nd of September 2015.
|
Ms Jane Catherine Bell | Non-Executive Director | Apr 2021 |
Ms Bell has more than 30 years' experience in leading law firms, financial services and corporate treasury operations in Melbourne, London, Toronto, San Francisco and Brisbane.
|
Dr Warwick Bonner Tong | Non-Executive DirectorNon-Executive Chairman | May 2018 |
Dr Tong is a NZ trained physician with more than 25 years' experience in the pharmaceutical and biotechnology industry. Dr Tong was appointed as a Non-Executive Director on 4th of May 2018 and Chairman on 25th May 2018.
|
Dr Christopher John Burns | Non Executive DirectorChief Executive OfficerManaging Director | May 2018 |
Dr Burns is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for 30 years. Dr Burns was originally appointed as a Non-Executive Director on 4th May 2018 and was subsequently appointed as Chief Executive Officer and Managing Director on 5th December 2022.
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 36,892,524 | 19.02% |
Bond Street Custodians Limited (Lam1 - D08047 A/C) | 13,472,500 | 6.94% |
BNP Paribas Noms Pty Ltd | 6,690,878 | 3.45% |
J P Morgan Nominees Australia Pty Limited | 6,052,184 | 3.12% |
Citicorp Nominees Pty Limited | 5,678,561 | 2.93% |
UBS Nominees Pty Ltd | 4,024,411 | 2.07% |
Ctxt Pty Ltd | 3,940,579 | 2.03% |
Elk River Holdings Pty Ltd | 3,067,142 | 1.58% |
Warwick Tong | 3,016,247 | 1.55% |
Christopher John Burns | 2,527,798 | 1.30% |
Gp Securities Pty Ltd | 2,412,500 | 1.24% |
34Th Avenue Pty Ltd (Devlin Family A/C) | 2,215,237 | 1.14% |
Heh Entreprises Pty Ltd (Heh Entreprises Invest A/C) | 2,050,000 | 1.06% |
Mrs Jane Catherine Jocelyn Bell + Mr Geoffrey Arthur Bell (Schooner Super Fund A/C) | 2,025,474 | 1.04% |
Mr Andrew Podolak | 1,925,000 | 0.99% |
Mr Anthony Hamilton Martin | 1,822,539 | 0.94% |
Robert James Peach + Cofactor Llc | 1,664,760 | 0.86% |
Mr Mark Sullivan | 1,661,428 | 0.86% |
Citicorp Nominees Pty Limited (Dpsl A/C) | 1,537,327 | 0.79% |
Swanmark Super Pty Ltd Rc (Swan Super Fund A/C) | 1,500,000 | 0.77% |